{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T20:40:31Z","timestamp":1711831231423},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s12288-010-0019-1","type":"journal-article","created":{"date-parts":[[2010,9,27]],"date-time":"2010-09-27T14:32:10Z","timestamp":1285597930000},"page":"30-40","source":"Crossref","is-referenced-by-count":6,"title":["Advances in Haematological Pharmacotherapy in 21st Century"],"prefix":"10.1007","volume":"26","author":[{"given":"Kanjaksha","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinjalka","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,28]]},"reference":[{"key":"19_CR1","first-page":"87","volume":"5","author":"K Ghosh","year":"1987","unstructured":"Ghosh K (1987) Advances in treatment of hematological disorders. Indian J Hematol Blood Transfus 5:87\u201394","journal-title":"Indian J Hematol Blood Transfus"},{"key":"19_CR2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM198701083160203","volume":"316","author":"JW Eschbach","year":"1987","unstructured":"Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of theanemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73\u201378","journal-title":"N Engl J Med"},{"issue":"8529","key":"19_CR3","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(87)91774-0","volume":"1","author":"J Bommer","year":"1987","unstructured":"Bommer J, M\u00fcller-B\u00fchl E, Ritz E, Eifert J (1987) Recombinant human erythropoietin in anaemic patients on haemodialysis. Lancet 1(8529):392\u2013393","journal-title":"Lancet"},{"key":"19_CR4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0146-0005(97)80016-X","volume":"21","author":"JJ Doyle","year":"1997","unstructured":"Doyle JJ (1997) The role of erythropoietin in the anemia of prematurity. Semin Perinatol 21:20\u201327","journal-title":"Semin Perinatol"},{"key":"19_CR5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00277-008-0450-7","volume":"87","author":"V Moyo","year":"2008","unstructured":"Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S (2008) Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 87:527\u2013536","journal-title":"Ann Hematol"},{"key":"19_CR6","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1378\/chest.105.3.856","volume":"105","author":"M Watanabe","year":"1994","unstructured":"Watanabe M, Kikuchi K, Kobayashi K, Ikeda Y, Handa M (1994) Autologous blood transfusion for pulmonary and mediastinal surgery in 144 patients. The effectiveness of recombinant erythropoietin injection. Chest 105:856\u2013859","journal-title":"Chest"},{"issue":"2A","key":"19_CR7","doi-asserted-by":"crossref","first-page":"22S","DOI":"10.1016\/S0002-9343(96)00165-9","volume":"101","author":"TH Price","year":"1996","unstructured":"Price TH, Goodnough LT, Vogler WR, Sacher RA, Hellman RM, Johnston MF, Bolgiano DC, Abels RI (1996) Improving the efficacy of preoperative autologous blood donation in patients with low hematocrit: a randomized, double-blind, controlled trial of recombinant human erythropoietin. Am J Med 101(2A):22S\u201327S","journal-title":"Am J Med"},{"key":"19_CR8","first-page":"648","volume":"3","author":"M Symann","year":"1991","unstructured":"Symann M (1991) Hematopoietic growth factors as supportive therapy for cancer- and chemotherapy-induced condition. Curr Opin Oncol 3:648\u2013655","journal-title":"Curr Opin Oncol"},{"key":"19_CR9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000204825","volume":"86","author":"EE Polli","year":"1991","unstructured":"Polli EE (1991) The role of haematopoietic growth factors in bone marrow transplantation. Acta Haematol 86:155\u2013161","journal-title":"Acta Haematol"},{"key":"19_CR10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/MOT.0b013e3282f42473","volume":"3","author":"JP Levesque","year":"2008","unstructured":"Levesque JP, Winkler IG (2008) Mobilization of hematopoietic stem cells: state of the art. Curr Opin Organ Transplant 3:53\u201358","journal-title":"Curr Opin Organ Transplant"},{"key":"19_CR11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/stem.5530130201","volume":"13","author":"DC Dale","year":"1995","unstructured":"Dale DC (1995) Hematopoietic growth factors for the treatment of severe chronic neutropenia. Stem Cells 13:94\u2013100","journal-title":"Stem Cells"},{"key":"19_CR12","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood.V81.10.2496.2496","volume":"81","author":"DC Dale","year":"1993","unstructured":"Dale DC, Bonilla MA, Davis MW, Nakanishi AM, Hammond WP, Kurtzberg J, Wang W, Jakubowski A, Winton E, Lalezari P et al (1993) A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 81:2496\u20132502","journal-title":"Blood"},{"key":"19_CR13","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood.V75.10.1951.1951","volume":"75","author":"AR Migliaccio","year":"1990","unstructured":"Migliaccio AR, Migliaccio G, Dale DC, Hammond WP (1990) Hematopoietic progenitors in cyclic neutropenia: effect of granulocyte colony-stimulating factor in vivo. Blood 75:1951\u20131959","journal-title":"Blood"},{"key":"19_CR14","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/sj.bmt.1701434","volume":"22","author":"M Karthaus","year":"1998","unstructured":"Karthaus M, Rosenthal C, Huebner G, Paul H, Elser C, Hertenstein B, Krauter J, Scharmann T, Geissler RG, Heil G, Ganser A (1998) Effect of topical oral G-CSF on oral mucositis: a randomised placebo-controlled trial. Bone Marrow Transplant 22:781\u2013785","journal-title":"Bone Marrow Transplant"},{"key":"19_CR15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0301-472X(98)00041-1","volume":"27","author":"A Bai","year":"1999","unstructured":"Bai A, Kojima H, Hori M, Nara N, Komeno T, Hasegawa Y, Ninomiya H, Abe T, Nagasawa T (1999) Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Exp Hematol 27:259\u2013265","journal-title":"Exp Hematol"},{"key":"19_CR16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199302183280701","volume":"328","author":"JM Lusher","year":"1993","unstructured":"Lusher JM, Arkin S, Abildgaard CF, Schwartz RS (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 328:453\u2013459","journal-title":"N Engl J Med"},{"key":"19_CR17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1182\/blood-2004-06-2283","volume":"105","author":"AD Shapiro","year":"2005","unstructured":"Shapiro AD, Di Paola J, Cohen A, Pasi KJ, Heisel MA, Blanchette VS, Abshire TC, Hoots WK, Lusher JM, Negrier C, Rothschild C, Roth DA (2005) The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 105:518\u2013525","journal-title":"Blood"},{"key":"19_CR18","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","volume":"109","author":"J Astermark","year":"2007","unstructured":"Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E, FENOC Study Group (2007) A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 109:546\u2013551","journal-title":"Blood"},{"key":"19_CR19","first-page":"717","volume":"53","author":"MB Agarwal","year":"2005","unstructured":"Agarwal MB, Patnaik M (2005) Recombinant activated factor VII (rFVIIa, NovoSeven). J Assoc Physicians India 53:717\u2013720","journal-title":"J Assoc Physicians India"},{"key":"19_CR20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/j.seminhematol.2007.04.005","volume":"44","author":"SO Ciurea","year":"2007","unstructured":"Ciurea SO, Hoffman R (2007) Cytokines for the treatment of thrombocytopenia. Semin Hematol 44:166\u2013182","journal-title":"Semin Hematol"},{"key":"19_CR21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/10428190600909115","volume":"48","author":"M Bhatia","year":"2007","unstructured":"Bhatia M, Davenport V, Cairo MS (2007) The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. Leuk Lymphoma 48:9\u201315","journal-title":"Leuk Lymphoma"},{"issue":"Suppl 1","key":"19_CR22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF03165282","volume":"76","author":"K Kaushansky","year":"2002","unstructured":"Kaushansky K (2002) Thrombopoietin: from theory to reality. Int J Hematol 76(Suppl 1):343\u2013345","journal-title":"Int J Hematol"},{"key":"19_CR23","first-page":"261","volume":"35","author":"S Vadhan-Raj","year":"1998","unstructured":"Vadhan-Raj S (1998) Recombinant human thrombopoietin: clinical experience and in vivo biology. Semin Hematol 35:261\u2013268","journal-title":"Semin Hematol"},{"key":"19_CR24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1006\/cyto.1997.0299","volume":"10","author":"J Hou","year":"1998","unstructured":"Hou J, Zhan H (1998) Expression of active thrombopoietin and identification of its key residues responsible for receptor binding. Cytokine 10:319\u2013330","journal-title":"Cytokine"},{"key":"19_CR25","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V99.7.2599","volume":"99","author":"RL Basser","year":"2002","unstructured":"Basser RL, O\u2019Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM, Cohen B, Begley CG (2002) Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 99:2599\u20132602","journal-title":"Blood"},{"key":"19_CR26","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1146\/annurev.med.60.042307.181154","volume":"60","author":"DJ Kuter","year":"2009","unstructured":"Kuter DJ (2009) Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med 60:193\u2013206","journal-title":"Annu Rev Med"},{"key":"19_CR27","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/CCO.0b013e32831369b2","volume":"20","author":"B Levy","year":"2008","unstructured":"Levy B, Arnason JE, Bussel JB (2008) The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia. Curr Opin Oncol 20:690\u2013696","journal-title":"Curr Opin Oncol"},{"key":"19_CR28","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2165\/00003495-200868070-00002","volume":"68","author":"R Stasi","year":"2008","unstructured":"Stasi R, Evangelista ML, Amadori S (2008) Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 68:901\u2013912","journal-title":"Drugs"},{"key":"19_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1423-0410.2007.00999.x","volume":"94","author":"S Panzer","year":"2008","unstructured":"Panzer S (2008) New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review. Vox Sang 94:1\u20135","journal-title":"Vox Sang"},{"key":"19_CR30","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1586\/egh.09.60","volume":"3","author":"C Fran\u00e7ois","year":"2009","unstructured":"Fran\u00e7ois C, Castelain S, Duverlie G, Capron D, Nguyen-Khac E (2009) Optimizing the treatment of chronic viral hepatitis C. Expert Rev Gastroenterol Hepatol 3:607\u2013613","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"19_CR31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1055\/s-0037-1613465","volume":"89","author":"ME Carr Jr","year":"2003","unstructured":"Carr ME Jr, Martin EJ, Kuhn JG, Seremetis SV (2003) Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Thromb Haemost 89:803\u2013811","journal-title":"Thromb Haemost"},{"key":"19_CR32","first-page":"579","volume":"6","author":"AD Shapiro","year":"2008","unstructured":"Shapiro AD (2008) Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors. Clin Adv Hematol Oncol 6:579\u2013586","journal-title":"Clin Adv Hematol Oncol"},{"key":"19_CR33","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0149-2918(01)80086-2","volume":"23","author":"L Davydov","year":"2001","unstructured":"Davydov L, Cheng JW (2001) Tenecteplase: a review. Clin Ther 23:982\u2013997","journal-title":"Clin Ther"},{"key":"19_CR34","first-page":"2","volume":"8","author":"KR Lees","year":"2009","unstructured":"Lees KR (2009) Stroke: success for extending acute treatment. Lancet(Neurol) 8:2\u20134","journal-title":"Lancet(Neurol)"},{"key":"19_CR35","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1345\/aph.10425","volume":"35","author":"NM Turcasso","year":"2001","unstructured":"Turcasso NM, Nappi JM (2001) Tenecteplase for treatment of acute yocardialinfarction. Ann Pharmacother 35:1233\u20131240","journal-title":"Ann Pharmacother"},{"key":"19_CR36","first-page":"481","volume":"2","author":"S Petros","year":"2001","unstructured":"Petros S (2001) Lepirudin in the management of patients with heparin-induced thrombocytopenia. Biologics 2:481\u2013490","journal-title":"Biologics"},{"key":"19_CR37","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1160\/TH09-05-0287","volume":"102","author":"G Luca De","year":"2009","unstructured":"De Luca G, Cassetti E, Verdoia M, Marino P (2009) Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: a meta-analysis of randomised trials. Thromb Haemost 102:428\u2013436","journal-title":"Thromb Haemost"},{"key":"19_CR38","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495\u2013497","journal-title":"Nature"},{"key":"19_CR39","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1182\/blood.V62.4.873.873","volume":"62","author":"G Hale","year":"1983","unstructured":"Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, Waldmann H (1983) Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 62:873\u2013882","journal-title":"Blood"},{"key":"19_CR40","doi-asserted-by":"crossref","unstructured":"Fisher RI, Miller TP, O\u2019Connor OA (2004) Diffuse aggressive lymphoma. Hematol Am Soc Hematol Educ Program 221\u2013236","DOI":"10.1182\/asheducation-2004.1.221"},{"key":"19_CR41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1756-8722-2-14","volume":"2","author":"G Siddhartha","year":"2009","unstructured":"Siddhartha G, Vijay P (2009) R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature. J Hematol Oncol 2:14\u201315","journal-title":"J Hematol Oncol"},{"key":"19_CR42","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","volume":"98","author":"R Stasi","year":"2001","unstructured":"Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98:952\u2013957","journal-title":"Blood"},{"key":"19_CR43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07054.x","volume":"141","author":"B Garvey","year":"2001","unstructured":"Garvey B (2001) Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 141:149\u2013169","journal-title":"Br J Haematol"},{"key":"19_CR44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MOH.0b013e328309ecab","volume":"15","author":"B Barnett","year":"2008","unstructured":"Barnett B, Kruse-Jarres R, Leissinger CA (2008) Current management of acquired factor VIII inhibitors. Curr Opin Hematol 15:451\u2013455","journal-title":"Curr Opin Hematol"},{"key":"19_CR45","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00001622-200111000-00016","volume":"13","author":"EL Sievers","year":"2001","unstructured":"Sievers EL, Linenberger M (2001) Myelotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol 13:522\u2013527","journal-title":"Curr Opin Oncol"},{"key":"19_CR46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.bbmt.2007.08.052","volume":"14","author":"D G\u00f3mez-Almaguer","year":"2008","unstructured":"G\u00f3mez-Almaguer D, Ruiz-Arg\u00fcelles GJ, del Carmen Tar\u00edn-Arzaga L, Gonz\u00e1lez-Llano O, Guti\u00e9rrez-Aguirre H, Cant\u00fa-Rodr\u00edguez O, Jaime-P\u00e9rez J, Carrasco-Yal\u00e1n A, Giralt S (2008) Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 14:10\u201315","journal-title":"Biol Blood Marrow Transplant"},{"key":"19_CR47","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.2009.008649","volume":"94","author":"B Patel","year":"2009","unstructured":"Patel B, Kirkland KE, Szydlo R, Pearce RM, Clark RE, Craddock C, Liakopoulou E, Fielding AK, Mackinnon S, Olavarria E, Potter MN, Russell NH, Shaw BE, Cook G, Goldstone AH, Marks DI (2009) Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica 94:1399\u20131406","journal-title":"Haematologica"},{"key":"19_CR48","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1097\/01.TP.0000158718.49286.14","volume":"79","author":"Y Kanda","year":"2005","unstructured":"Kanda Y, Oshima K, Asano-Mori Y, Kandabashi K, Nakagawa M, Sakata-Yanagimoto M, Izutsu K, Hangaishi A, Tsujino S, Ogawa S, Motokura T, Chiba S, Hirai H (2005) In vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation 79:1351\u20131357","journal-title":"Transplantation"},{"key":"19_CR49","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJMoa031688","volume":"350","author":"P Hillmen","year":"2004","unstructured":"Hillmen P, Hall C, Marsh JC, Elebute M, Bombara MP, Petro BE, Cullen MJ, Richards SJ, Rollins SA, Mojcik CF, Rother RP (2004) Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 350:552\u2013559","journal-title":"N Engl J Med"},{"key":"19_CR50","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/lt.21417","volume":"14","author":"A Mitchell","year":"2008","unstructured":"Mitchell A, Adams LA, MacQuillan G, Tibballs J, vanden Driesen R, Delriviere L (2008) Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 14:210\u2013213","journal-title":"Liver Transpl"},{"key":"19_CR51","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1161\/01.CIR.90.4.1757","volume":"90","author":"JE Tcheng","year":"1994","unstructured":"Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ (1994) Pharmacodynamics of chimeric glycoprotein IIb\/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 90:1757\u20131764","journal-title":"Circulation"},{"key":"19_CR52","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.beha.2005.01.002","volume":"19","author":"A Farrugia","year":"2006","unstructured":"Farrugia A, Robert P (2006) Plasma protein therapies: current and future perspectives. Best Pract Res Clin Haematol 19:243\u2013258","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6 Suppl","key":"19_CR53","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/1097-0142(19910915)68:6+<1454::AID-CNCR2820681409>3.0.CO;2-F","volume":"68","author":"T Abe","year":"1991","unstructured":"Abe T, Kawasugi K (1991) Use of intravenous immunoglobulin in various medical conditions. A Japanese experience. Cancer 68(6 Suppl):1454\u20131459","journal-title":"Cancer"},{"key":"19_CR54","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/08880010903540542","volume":"27","author":"B George","year":"2010","unstructured":"George B, Mathews V, Viswabandya A, Lakshmi KM, Srivastava A, Chandy M (2010) Allogeneic hematopoietic stem cell transplantation is superior to immunosuppressive therapy in Indian children with aplastic anemia-a single-center analysis of 100 patients. Pediatr Hematol Oncol 27:122\u2013131","journal-title":"Pediatr Hematol Oncol"},{"key":"19_CR55","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/sj.leu.2403239","volume":"18","author":"M Stadler","year":"2004","unstructured":"Stadler M, Germing U, Kliche KO, Josten KM, Kuse R, Hofmann WK, Schrezenmeier H, Novotny J, Anders O, Eimermacher H, Verbeek W, Kreipe HH, Heimpel H, Aul C, Ganser A (2004) A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18:460\u2013465","journal-title":"Leukemia"},{"key":"19_CR56","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1182\/blood-2003-08-2803","volume":"102","author":"M Madkaikar","year":"2003","unstructured":"Madkaikar M, Ghosh K (2003) Treating patients of myelodysplastic syndrome with antithymocytic globulin\u2013should we be more selective? Blood 102:3851\u20133852","journal-title":"Blood"},{"key":"19_CR57","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/sj.bmt.1701645","volume":"23","author":"TH Eiermann","year":"1999","unstructured":"Eiermann TH, Lambrecht P, Zander AR (1999) Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. Bone Marrow Transplant 23:779\u2013781","journal-title":"Bone Marrow Transplant"},{"key":"19_CR58","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0936-6555(05)80661-2","volume":"8","author":"D Bissett","year":"1996","unstructured":"Bissett D, Kaye SB, Baxter G, Moss J (1996) Successful thrombolysis of SVC thrombosis associated with Hickman lines and continuous infusion chemotherapy. Clin Oncol (R Coll Radiol) 8:247\u2013249","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"7S","key":"19_CR59","first-page":"1857","volume":"113","author":"GK Dy","year":"2008","unstructured":"Dy GK, Adjei AA (2008) Systemic cancer therapy: evolution over the last 60\u00a0years. Cancer 113(7S):1857\u20131887","journal-title":"Cancer"},{"key":"19_CR60","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.clinthera.2009.11.031","volume":"31","author":"TW Dennie","year":"2009","unstructured":"Dennie TW, Kolesar JM (2009) Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Clin Ther 31:2290\u20132311","journal-title":"Clin Ther"},{"key":"19_CR61","doi-asserted-by":"crossref","unstructured":"Hallek M (2009) State-of-the-art treatment of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program 440\u2013449","DOI":"10.1182\/asheducation-2009.1.440"},{"key":"19_CR62","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.hoc.2006.06.001","volume":"20","author":"MR Grever","year":"2006","unstructured":"Grever MR (2006) Pentostatin: impact on outcome in hairy cell leukemia. Hematol Oncol Clin North Am 20:1099\u20131108","journal-title":"Hematol Oncol Clin North Am"},{"key":"19_CR63","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1182\/blood-2009-10-251645","volume":"115","author":"DS Sigal","year":"2010","unstructured":"Sigal DS, Sharpe R, Burian C, Saven A (2010) Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 115:1893\u20131896","journal-title":"Blood"},{"issue":"Suppl 2","key":"19_CR64","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.seminhematol.2005.12.007","volume":"43","author":"FM Foss","year":"2006","unstructured":"Foss FM (2006) The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation. Semin Hematol 43(Suppl 2):S35\u2013S43","journal-title":"Semin Hematol"},{"key":"19_CR65","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.23915","volume":"113","author":"SR Pasricha","year":"2008","unstructured":"Pasricha SR, Grigg A, Catalano J, Leahy M, Underhill C, Arthur C, D\u2019Rozario J, Lowenthal R, Reed K, Spencer A (2008) A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma. Cancer 113:3192\u20133198","journal-title":"Cancer"},{"key":"19_CR66","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/beha.2000.0119","volume":"14","author":"EJ Dann","year":"2001","unstructured":"Dann EJ, Rowe JM (2001) Biology and therapy of secondary leukaemias. Best Pract Res Clin Haematol 14:119\u2013137","journal-title":"Best Pract Res Clin Haematol"},{"key":"19_CR67","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3816\/CLM.2009.n.056","volume":"9","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV (2009) Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 9:278\u2013288","journal-title":"Clin Lymphoma Myeloma"},{"key":"19_CR68","doi-asserted-by":"crossref","unstructured":"Harousseau JL (2008) Induction therapy in multiple myeloma. Hematol Am Soc Hematol Educ Program 306\u2013312","DOI":"10.1182\/asheducation-2008.1.306"},{"key":"19_CR69","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1200\/JCO.2005.03.6715","volume":"24","author":"SD Nimer","year":"2006","unstructured":"Nimer SD (2006) Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol 24:2576\u20132582","journal-title":"J Clin Oncol"},{"key":"19_CR70","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.beha.2009.01.001","volume":"22","author":"F Elice","year":"2009","unstructured":"Elice F, Rodeghiero F, Falanga A, Rickles FR (2009) Thrombosis associated with angiogenesis inhibitors. Best Pract Res Clin Haematol 22:115\u2013128","journal-title":"Best Pract Res Clin Haematol"},{"key":"19_CR71","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1046\/j.1365-2141.2000.02480.x","volume":"111","author":"GA Kennedy","year":"2000","unstructured":"Kennedy GA, Marlton P, Cobcroft R, Gill D (2000) Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide\/ATRA consolidation in a Jehovah\u2019s Witness with de novo acute promyelocytic leukaemia. Br J Haematol 111:1103\u20131105","journal-title":"Br J Haematol"},{"key":"19_CR72","first-page":"389","volume":"25","author":"AB Glassman","year":"1995","unstructured":"Glassman AB (1995) Cytogenetics, gene fusions, and cancer. Ann Clin Lab Sci 25:389\u2013393","journal-title":"Ann Clin Lab Sci"},{"key":"19_CR73","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031\u20131037","journal-title":"N Engl J Med"},{"key":"19_CR74","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.leu.2402041","volume":"15","author":"J Topaly","year":"2001","unstructured":"Topaly J, Zeller WJ, Fruehauf S (2001) Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 15:342\u2013347","journal-title":"Leukemia"},{"key":"19_CR75","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1158\/1078-0432.CCR-09-2760","volume":"16","author":"P le Coutre","year":"2010","unstructured":"le Coutre P, Schwarz M, Kim TD (2010) New developments in tyrosine kinase inhibitor therapy for newly diagnosed chronic myeloid leukemia. Clin Cancer Res 16:1771\u20131780","journal-title":"Clin Cancer Res"},{"key":"19_CR76","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/bmt.2008.218","volume":"42","author":"H Bittencourt","year":"2008","unstructured":"Bittencourt H, Funke V, Fogliatto L, Magalh\u00e3es S, Setubal D, Paz A, Macedo AV, Ruiz J, Azambuja AP, Silla L, Clementino N, Pasquini R (2008) Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. Bone Marrow Transplant 42:597\u2013600","journal-title":"Bone Marrow Transplant"},{"key":"19_CR77","doi-asserted-by":"crossref","unstructured":"Bixby D, Talpaz M (2009) Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematol Am Soc Hematol Educ Program 461\u2013476","DOI":"10.1182\/asheducation-2009.1.461"},{"key":"19_CR78","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2141.2009.07599.x","volume":"145","author":"GJ Gleich","year":"2009","unstructured":"Gleich GJ, Leiferman KM (2009) The hypereosinophilic syndromes: current concepts and treatments. Br J Haematol 145:271\u2013285","journal-title":"Br J Haematol"},{"key":"19_CR79","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0145-2126(97)00036-2","volume":"21","author":"XM Sheng","year":"1997","unstructured":"Sheng XM, Kawamura M, Ohnishi H, Ida K, Hanada R, Kojima S, Kobayashi M, Bessho F, Yanagisawa M, Hayashi Y (1997) Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia. Leuk Res 21:697\u2013701","journal-title":"Leuk Res"},{"key":"19_CR80","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2141.2008.07099.x","volume":"141","author":"T Braun","year":"2008","unstructured":"Braun T, Fenaux P (2008) Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 141:576\u2013586","journal-title":"Br J Haematol"},{"key":"19_CR81","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/978-3-642-01222-8_14","volume":"184","author":"A Gontarewicz","year":"2010","unstructured":"Gontarewicz A, Br\u00fcmmendorf TH (2010) Danusertib (formerly PHA-739358)\u2013a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Recent Results Cancer Res 184:199\u2013214","journal-title":"Recent Results Cancer Res"},{"key":"19_CR82","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.beha.2007.11.002","volume":"21","author":"AD Schimmer","year":"2008","unstructured":"Schimmer AD (2008) Apoptosis in leukemia: from molecular pathways to targeted therapies. Best Pract Res Clin Haematol 21:5\u201311","journal-title":"Best Pract Res Clin Haematol"},{"key":"19_CR83","doi-asserted-by":"crossref","unstructured":"Hallek M (2009) State-of-the-art treatment of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program 440\u2013449","DOI":"10.1182\/asheducation-2009.1.440"},{"key":"19_CR84","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.hoc.2009.07.001","volume":"23","author":"K Mr\u00f3zek","year":"2009","unstructured":"Mr\u00f3zek K, Harper DP, Aplan PD (2009) Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am 23:991\u20131010 v","journal-title":"Hematol Oncol Clin North Am"},{"key":"19_CR85","first-page":"489","volume":"134","author":"J DeSimone","year":"1983","unstructured":"DeSimone J, Heller P, Schimenti JC, Duncan CH (1983) Fetal hemoglobin production in adult baboons by 5-azacytidine or by phenylhydrazine-induced hemolysis is associated with hypomethylation of globin gene DNA. Prog Clin Biol Res 134:489\u2013500","journal-title":"Prog Clin Biol Res"},{"key":"19_CR86","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/era.09.164","volume":"10","author":"FP Santos","year":"2010","unstructured":"Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F (2010) Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther 10:9\u201322","journal-title":"Expert Rev Anticancer Ther"},{"key":"19_CR87","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1158\/1078-0432.CCR-04-0210","volume":"10","author":"P Bali","year":"2004","unstructured":"Bali P, George P, Cohen P, Tao J, Guo F, Sigua C, Vishvanath A, Scuto A, Annavarapu S, Fiskus W, Moscinski L, Atadja P, Bhalla K (2004) Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3. Clin Cancer Res 10:4991\u20134997","journal-title":"Clin Cancer Res"},{"key":"19_CR88","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-3-642-01222-8_12","volume":"184","author":"H Einsele","year":"2010","unstructured":"Einsele H (2010) Bortezomib. Recent Results Cancer Res 184:173\u2013187","journal-title":"Recent Results Cancer Res"},{"key":"19_CR89","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3816\/CLM.2009.n.056","volume":"9","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV (2009) Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 9:278\u2013288","journal-title":"Clin Lymphoma Myeloma"},{"key":"19_CR90","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/PPO.0b013e3181c51cba","volume":"15","author":"SK Thomas","year":"2009","unstructured":"Thomas SK, Richards TA, Weber DM (2009) Novel agents for relapsed and\/or refractory multiple myeloma. Cancer J 15:485\u2013493","journal-title":"Cancer J"},{"issue":"Suppl 8A","key":"19_CR91","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1016\/j.amjmed.2005.06.005","volume":"118","author":"LB Menajovsky","year":"2005","unstructured":"Menajovsky LB (2005) Heparin-induced thrombocytopenia: clinical manifestations and management strategies. Am J Med 118(Suppl 8A):21S\u201330S","journal-title":"Am J Med"},{"key":"19_CR92","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1055\/s-0029-1145260","volume":"34","author":"J Harenberg","year":"2008","unstructured":"Harenberg J (2008) Development of new anticoagulants: present and future. Semin Thromb Hemost 34:779\u2013793","journal-title":"Semin Thromb Hemost"},{"key":"19_CR93","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1517\/14740338.6.4.397","volume":"6","author":"L Testa","year":"2007","unstructured":"Testa L, Bhindi R, Agostoni P, Abbate A, Zoccai GG, van Gaal WJ (2007) The direct thrombin inhibitor ximelagatran\/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert Opin Drug Saf 6:397\u2013406","journal-title":"Expert Opin Drug Saf"},{"key":"19_CR94","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1517\/14656560903413559","volume":"10","author":"N Fassiadis","year":"2009","unstructured":"Fassiadis N (2009) Rivaroxaban, the first oral, direct factor Xa inhibitor. Expert Opin Pharmacother 10:2945\u20132946","journal-title":"Expert Opin Pharmacother"},{"key":"19_CR95","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","volume":"36","author":"S Schulman","year":"2009","unstructured":"Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, RE-COVER Study Group (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 36:2342\u20132352","journal-title":"N Engl J Med"},{"key":"19_CR96","first-page":"304","volume":"32","author":"PJ Giardina","year":"1995","unstructured":"Giardina PJ, Grady RW (1995) Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine. Semin Hematol 32:304\u2013312","journal-title":"Semin Hematol"},{"key":"19_CR97","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2141.1992.tb06445.x","volume":"82","author":"MB Agarwal","year":"1992","unstructured":"Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, Puniyani RR, Chhablani AT (1992) Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 82:460\u2013466","journal-title":"Br J Haematol"},{"key":"19_CR98","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1067\/mlc.2001.116487","volume":"138","author":"G Link","year":"2001","unstructured":"Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C (2001) Exploring the \u201ciron shuttle\u201d hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 138:130\u2013138","journal-title":"J Lab Clin Med"},{"issue":"Suppl 1","key":"19_CR99","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.3109\/03630260903347146","volume":"33","author":"JB Porter","year":"2009","unstructured":"Porter JB (2009) Deferasirox: an update. Hemoglobin 33(Suppl 1):S70\u2013S75","journal-title":"Hemoglobin"},{"issue":"2 Suppl 1","key":"19_CR100","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/shem.2002.33611","volume":"39","author":"Z Chen","year":"2002","unstructured":"Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY, Chen SJ (2002) Expanding the use of arsenic trioxide: leukemias and beyond. Semin Hematol 39(2 Suppl 1):22\u201326","journal-title":"Semin Hematol"},{"key":"19_CR101","unstructured":"Ware RE, Aygun B (2009) Advances in the use of hydroxyurea. Hematol Am Soc Hematol Educ Program 62\u201369"},{"issue":"1\u20132","key":"19_CR102","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cca.2009.06.019","volume":"407","author":"KY Italia","year":"2009","unstructured":"Italia KY, Jijina FJ, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB (2009) Response to hydroxyurea in beta thalassemia major and intermedia: experience in western India. Clin Chim Acta 407(1\u20132):10\u201315","journal-title":"Clin Chim Acta"},{"key":"19_CR103","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/09537100802315110","volume":"19","author":"SM Vancine-Califani","year":"2008","unstructured":"Vancine-Califani SM, De Paula EV, Ozelo MC, Orsi FL, Fabri DR, Annichino-Bizzacchi JM (2008) Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura. Platelets 19:489\u2013495","journal-title":"Platelets"},{"key":"19_CR104","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1053\/sonc.2003.50044","volume":"30","author":"M Coleman","year":"2003","unstructured":"Coleman M, Leonard J, Lyons L, Szelenyi H, Niesvizky R (2003) Treatment of Waldenstrom\u2019s macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Semin Oncol 30:270\u2013274","journal-title":"Semin Oncol"},{"key":"19_CR105","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12288-008-0038-3","volume":"24","author":"K Ghosh","year":"2008","unstructured":"Ghosh K, Ghosh K (2008) Management of chronic synovitis in patients with hemophilia: with special reference to developing countries. Ind J Haematol Blood Transf 24:151\u2013154","journal-title":"Ind J Haematol Blood Transf"},{"key":"19_CR106","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jca.10021","volume":"17","author":"P Perseghin","year":"2002","unstructured":"Perseghin P, Dassi M, Balduzzi A, Rovelli A, Bonanomi S, Uderzo C (2002) Mononuclear cell collection in patients undergoing extra-corporeal photo-chemotherapy for acute and chronic graft-vs.-host-disease (GvHD): comparison between COBE Spectra version 4.7 and 6.0 (AutoPBSC). J Clin Apher 17:65\u201371","journal-title":"J Clin Apher"},{"issue":"Pt 1","key":"19_CR107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1470-8744.1999.tb01153.x","volume":"30","author":"L Villeneuve","year":"1999","unstructured":"Villeneuve L (1999) Ex vivo photodynamic purging in chronic myelogenous leukaemia and other neoplasias with rhodamine derivatives. Biotechnol Appl Biochem 30(Pt 1):1\u201317","journal-title":"Biotechnol Appl Biochem"},{"key":"19_CR108","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/iub.284","volume":"62","author":"M Beck","year":"2010","unstructured":"Beck M (2010) Therapy for lysosomal storage disorders. IUBMB Life 62:33\u201340","journal-title":"IUBMB Life"},{"key":"19_CR109","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMe078027","volume":"356","author":"SV Rajkumar","year":"2007","unstructured":"Rajkumar SV, Gertz MA (2007) Advances in the treatment of amyloidosis. N Engl J Med 356:2413\u20132415","journal-title":"N Engl J Med"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-010-0019-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12288-010-0019-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-010-0019-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T20:00:49Z","timestamp":1711828849000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12288-010-0019-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":109,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["19"],"URL":"https:\/\/doi.org\/10.1007\/s12288-010-0019-1","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}